Market Capitalization Summary - TAL Education Group has a market capitalization of 14.304 billion [2] - New Oriental Education has a market capitalization of 9.513 billion [2] - 51Talk has a market capitalization of 8.451 billion [2] - Zai Lab has a market capitalization of 7.849 billion [2] - BeiGene has a market capitalization of 6.377 billion [2] - 78.69 billion market capitalization for an unspecified company [2] Stock Performance - TAL Education Group's stock changed by -0.04 (-0.20%) [2] - New Oriental Education's stock increased by +0.12 (+0.56%) [2] - 51Talk's stock increased by +1.00 (+1.97%) [2] - Zai Lab's stock increased by +0.07 (+1.91%) [2] - BeiGene's stock increased by +0.28 (+1.91%) [2] - 78.69 billion market capitalization company increased by +0.24 (+2.40%) [2] Additional Companies and Market Data - JD Health has a market capitalization of 6.009 billion [2] - SOS Limited has a market capitalization of 3.883 billion [2] - Miniso Group has a market capitalization of 5.764 billion [2] - Lufax Holding has a market capitalization of 1.791 billion [2] - iQIYI has a market capitalization of 2.392 billion [2] - Weibo has a market capitalization of 1.791 billion [2] Performance Changes - JD Health's stock decreased by -0.10 (-0.51%) [2] - SOS Limited's stock increased by +1.22 (+2.80%) [2] - Miniso Group's stock decreased by -0.52 (-1.47%) [2] - Lufax Holding's stock increased by +0.26 (+2.65%) [2] - iQIYI's stock increased by +0.09 (+5.08%) [2]

Market Capitalization Overview - NIO has a market capitalization of 143.32 billion, while TAL Education has 94.60 billion [2] - Vipshop's market cap stands at 76.95 billion, with a stock price change of -0.04 (-0.30%) [2] - Zai Lab has a market cap of 58.43 billion, showing a price increase of +0.34 (+0.79%) [2] Stock Performance - NIO's stock price decreased by -0.13 (-0.72%), while TAL Education's increased by +1.60 (+7.66%) [2] - Vipshop's stock price decreased by -0.09 (-2.56%), whereas Zai Lab's increased by +0.47 (+2.61%) [2] - The stock price of iQIYI increased by +0.01 (+0.28%) with a market cap of 23.75 billion [2] Notable Changes - Sohu's market cap is 4.03 billion, with a stock price decrease of -0.37 (-2.69%) [4] - Tianjing Bio's stock price surged by +1.05 (+32.31%) despite a market cap of only 1.80 billion [4] - Huami's market cap is 4971.35 million, with a stock price increase of +0.48 (+16.11%) [4]

Market Capitalization Summary - NIO has a market capitalization of 14.456 billion [2] - TAL Education Group has a market capitalization of 9.393 billion [2] - Vipshop Holdings has a market capitalization of 8.466 billion [2] - Zai Lab has a market capitalization of 5.900 billion [2] - Huya has a market capitalization of 5.58 billion [2] Stock Performance - NIO's stock increased by 0.03 (+0.14%) [2] - TAL Education Group's stock increased by 1.44 (+6.90%) [2] - Vipshop Holdings' stock increased by 0.29 (+0.56%) [2] - Zai Lab's stock increased by 0.52 (+2.88%) [2] - Huya's stock decreased by 0.23 (-6.02%) [2] Additional Company Insights - New Oxygen has a market capitalization of 0.281 billion with a stock increase of 0.70 (+21.69%) [4] - Financial One Account has a market capitalization of 0.396 billion with no change in stock price [4] - Thunder has a market capitalization of 0.278 billion with a stock decrease of 0.10 (-2.20%) [4] - Xiaoniu Electric has a market capitalization of 0.231 billion with a stock increase of 0.07 (+1.93%) [4]

Market Capitalization Overview - The market capitalizations of various companies are listed, with TAL Education Group at 14.42 billion, Vipshop at 8.78 billion, and others like 7.73 billion for Miniso and 5.33 billion for Yiren Digital [2]. - Notable changes in stock prices include a decrease of 0.01 (-0.06%) for TAL Education and an increase of 0.34 (+0.81%) for Miniso [2]. Company Performance - Companies such as New Oxygen and Thunder have market capitalizations of 2.83 million and 2.82 million respectively, with New Oxygen showing a significant increase of 0.67 (+19.97%) [3]. - Other companies like Baozun and Cheetah Mobile have market capitalizations of 1.52 million and 1.24 million respectively, with Baozun experiencing a slight decrease of 0.01 (-0.26%) [3]. Stock Price Movements - The stock price movements indicate a mix of increases and decreases across various companies, with notable gains for companies like New Oxygen and Miniso, while others like TAL Education and Yiren Digital show slight declines [2][3]. - The overall market sentiment appears to be varied, with some companies experiencing positive momentum while others face downward pressure [2][3].

Core Insights - I-Mab announced positive Phase 1b combination data for givastomig, showing a confirmed objective response rate (ORR) of 83% at selected doses for ongoing expansion studies [1][2][3] - The study demonstrated favorable tolerability and safety profile, with no Grade 3 or greater events for nausea and vomiting [2][21] - Givastomig is a bispecific antibody targeting Claudin 18.2 and 4-1BB, being developed for first-line treatment of Claudin 18.2-positive gastric cancers [15][18] Study Results - The Phase 1b study showed an overall ORR of 71% across all doses and 83% at doses selected for expansion (8 mg/kg and 12 mg/kg) [2][10] - Responses were observed in tumors with low PD-L1 and/or Claudin 18.2 expression, indicating broad potential for the therapy [2][3] - The disease control rate (DCR) was 100% across all dose levels, with a median follow-up of 9.0 months [12][13] Safety Profile - Treatment-related adverse events (TRAEs) leading to discontinuation were 12%, with common TRAEs being Grade 1 or 2 [21] - No dose-limiting toxicities (DLT) were observed, and a maximum tolerated dose (MTD) was not reached [21] - Grade 3 TRAEs were rare, with only isolated cases reported [21] Future Plans - I-Mab plans to host a virtual investor event on July 8 to discuss the Phase 1b data further [1][4] - The ongoing Phase 1b study is evaluating givastomig in combination with nivolumab and chemotherapy, with enrollment progressing ahead of schedule [16][18]

Market Capitalization Summary - TAL Education Group has a market capitalization of 14.284 billion [2] - Vipshop Holdings has a market capitalization of 8.942 billion [2] - 51Talk has a market capitalization of 7.770 billion [2] - New Oriental Education has a market capitalization of 6.304 billion [2] - 58.com has a market capitalization of 5.867 billion [2] Stock Performance - TAL Education Group's stock increased by 0.11 (+0.62%) [2] - Vipshop Holdings' stock decreased by 0.08 (-0.37%) [2] - 51Talk's stock increased by 0.12 (+0.22%) [2] - New Oriental Education's stock increased by 0.04 (+1.31%) [2] - 58.com’s stock increased by 0.28 (+0.63%) [2] Additional Company Insights - New Oriental Education's stock price is 18.29 [2] - Vipshop Holdings' stock price is 15.09 [2] - TAL Education Group's stock price is 3.48 [2] - 51Talk's stock price is 10.34 [2] - 58.com’s stock price is 12.00 [2]

Core Insights - I-Mab announced the publication of first-in-human monotherapy data for givastomig, a bispecific Claudin 18.2 x 4-1BB antibody, showing an objective response rate (ORR) of 16% in heavily pretreated Claudin 18.2-positive gastric cancer patients [1][2][4] Summary of Monotherapy Results - The Phase 1 monotherapy study evaluated 75 patients, with 43 being efficacy-evaluable for advanced or metastatic gastroesophageal carcinoma (GEC) [2][5] - The ORR increased to 18% after the enrollment of two additional patients, resulting in 8 out of 45 patients achieving a confirmed partial response (PR) [2][6] - The study demonstrated a disease control rate (DCR) of 49% among the efficacy-evaluable patients [7] Safety and Tolerability - Givastomig was well tolerated, with no dose-limiting toxicity reported up to 15 mg/kg dosed every two weeks and 18 mg/kg dosed every three weeks [15] - The most common treatment-related adverse events were mainly Grade 1 or 2 [15] Development Strategy - The findings support the development of givastomig in combination with standard immunochemotherapy (nivolumab plus mFOLFOX6) as a first-line treatment for gastric cancers [3][4] - An ongoing Phase 1b study is evaluating givastomig in combination with nivolumab and chemotherapy, with enrollment progressing ahead of schedule [10] Unique Mechanism - Givastomig's bispecific design allows for high binding affinity to Claudin 18.2-positive cancer cells, enabling localized T cell stimulation while minimizing gastrointestinal toxicity [4][9]

Core Insights - I-Mab announced positive data from a Phase 1b study of givastomig in combination with nivolumab and mFOLFOX6 for metastatic gastric cancers, showing an objective response rate (ORR) of 71% across all dose levels and 83% in the selected dose expansion cohort [1][2][3] Study Details - The Phase 1b study evaluated the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of givastomig as first-line therapy in Claudin 18.2-positive gastric cancers, with a primary endpoint focused on safety [2][18] - The study enrolled 17 treatment-naïve patients with advanced metastatic gastric, esophageal, or gastroesophageal adenocarcinomas [6][18] Efficacy Results - Overall, 71% (12/17) of patients achieved a partial response (PR) per RECIST v1.1, with a higher response rate of 83% (10/12) in the dose levels selected for expansion (8 and 12 mg/kg) [9][13] - The disease control rate (DCR) was reported at 100% across all dose levels [13] - Notably, responses were observed in patients with low PD-L1 and/or CLDN18.2 expression [1][3] Safety Profile - The safety profile of givastomig was favorable, with no dose-limiting toxicities (DLT) observed and a maximum tolerated dose (MTD) not reached [14][15] - Common treatment-related adverse events (TRAEs) were generally Grade 1 or Grade 2, including nausea, vomiting, and fatigue, with rare Grade 3 TRAEs reported [14][15] Upcoming Events - Updated results from the study will be presented at the ESMO GI 2025 on July 2nd, and the company will host a virtual investor event on July 8th to discuss the findings [1][12]

Market Capitalization Summary - NIO has a market capitalization of 14.376 billion [2] - TAL Education has a market capitalization of 8.903 billion [2] - Vipshop has a market capitalization of 8.852 billion [2] - Miniso has a market capitalization of 6.079 billion [2] - JD Health has a market capitalization of 5.543 billion [2] Stock Performance - NIO's stock increased by 0.36 (+2.07%) [2] - TAL Education's stock decreased by 1.06 (-1.91%) [2] - Vipshop's stock decreased by 0.33 (-2.95%) [2] - Miniso's stock decreased by 0.59 (-1.29%) [2] - JD Health's stock decreased by 0.14 (-0.78%) [2] Additional Company Insights - Lufax Holdings has a market capitalization of 2.443 billion [2] - Huya has a market capitalization of 0.786 billion [3] - Xiaoniu Electric has a market capitalization of 0.286 billion [3] - Cheetah Mobile has a market capitalization of 0.116 billion [3] - Yunmi has a market capitalization of 0.094 billion [3]

Market Capitalization Summary - TAL Education Group has a market capitalization of 14.104 billion [2] - Vipshop Holdings has a market capitalization of 8.066 billion [2] - 7.705 billion market capitalization for SouFun Holdings [2] - 6.042 billion market capitalization for WuXi AppTec [2] - 2.461 billion market capitalization for Lufax Holding [2] Stock Performance - TAL Education Group's stock increased by 0.75 (+3.77%) [2] - Vipshop Holdings' stock rose by 0.34 (+2.29%) [2] - SouFun Holdings saw a stock increase of 1.75 (+4.05%) [2] - WuXi AppTec's stock increased by 0.70 (+2.75%) [2] - Lufax Holding's stock rose by 0.05 (+1.79%) [2] Additional Company Insights - The stock of iQIYI increased by 0.38 (+4.04%) with a market cap of 2.417 billion [2] - Xunlei's market capitalization is 2.74 billion with a stock increase of 0.09 (+2.09%) [4] - The market cap of Huami is 0.1758 billion with a stock increase of 0.02 (+0.98%) [4]